Welcome to our dedicated page for Steris Plc SEC filings (Ticker: STE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
STERIS plc filings document material events for an Ireland-incorporated operating company with ordinary shares traded as STE on the New York Stock Exchange. Recent Form 8-K reports cover results of operations and financial condition, attached earnings releases, director appointments and retirements, officer transition arrangements, and compensation-related amendments.
The filing record also identifies STERIS securities registered under Section 12(b), including ordinary shares and NYSE-listed senior notes due 2031 and 2051. These disclosures frame the company’s capital structure, governance actions, executive-compensation matters, and periodic operating-result announcements for its infection-prevention and life sciences business.
STERIS plc executive Renato Tamaro, Vice President & Corporate Treasurer, reported routine equity compensation changes. He received 750 ordinary shares as a grant and a new employee stock option for 2,620 ordinary shares at an exercise price of $230.74 per share, expiring on June 2, 2036. To cover tax obligations on previously granted restricted stock, 41 shares were withheld from 141 restricted shares that vested on June 2, 2026, a tax-withholding disposition rather than an open-market sale. Following these transactions, Tamaro holds 6,364 ordinary shares directly, of which 1,843 shares are restricted as of June 2, 2026 and scheduled to vest in tranches between June 3, 2026 and June 4, 2029.
STERIS plc VP Lindsey McGowan reported routine equity compensation changes. On June 2, 2026, 1,128 restricted ordinary shares vested, and 329 shares were withheld at $209.76 per share to cover tax obligations, leaving 5,656 ordinary shares held directly.
McGowan also received a new grant of 1,155 ordinary shares, increasing direct holdings to 5,985 shares, of which 3,117 are restricted as of June 2, 2026. In addition, she was granted 4,036 employee stock options exercisable at $230.74 per share, expiring on June 2, 2036, vesting in four equal annual installments starting in 2027.
Separately, 255 ordinary share equivalents are held for her account under the STERIS Corporation 401(k) Plan as of May 29, 2026. These transactions reflect compensation grants and tax withholding rather than open-market buying or selling.
STERIS plc senior executive Cary L. Majors reported routine equity compensation and related tax withholding. On June 2, 2026, he received a grant of 4,746 ordinary shares, bringing his direct holdings to 17,405 shares. A separate entry shows 67 shares disposed at $209.76 per share solely to satisfy tax obligations on 2,140 restricted shares that vested the same day.
Majors was also granted an employee stock option for 16,548 ordinary shares at an exercise price of $230.74 per share, expiring on June 2, 2036. As of June 2, 2026, 10,047 of his ordinary shares are restricted, scheduled to vest in stages through June 4, 2029. In addition, units representing 67 ordinary share equivalents are held for him under the STERIS Corporation 401(k) Plan.
STERIS plc senior vice president Julia Madsen reported routine equity compensation activity. She received 2,316 ordinary shares as a stock award and a new employee stock option covering 8,080 ordinary shares at an exercise price of $230.74 per share, expiring on June 2, 2036. To cover tax obligations on 352 restricted shares that vested on June 2, 2026, 127 shares were withheld by the company, which is recorded as a tax-withholding disposition rather than an open-market sale. After these transactions, she holds 12,818 ordinary shares directly, of which 5,398 are restricted shares scheduled to vest in tranches between June 2026 and June 2029.
STERIS plc senior executive Kenneth E. Kohler reported routine equity compensation and related tax withholding. He received 2,199 ordinary shares as a grant and 7,668 employee stock options to buy ordinary shares at $230.74 per share, expiring on June 2, 2036.
The filing also shows 66 ordinary shares valued at $209.76 each were withheld to cover taxes on 225 restricted shares that vested on June 2, 2026, rather than sold in the market. After these transactions, he directly holds 11,732 ordinary shares, including 5,115 restricted shares that vest in stages through June 4, 2029.
STERIS plc SVP & Chief HRO Mary Clare Fraser reported routine equity compensation and related tax withholding. She received 3,009 ordinary shares at no cost and a grant of 10,492 employee stock options exercisable at $230.74 per share, expiring on June 2, 2036. As part of 2,028 restricted shares that vested on June 2, 2026, 591 shares valued at $209.76 per share were withheld to cover taxes. Following these transactions, she holds 15,218 ordinary shares directly, of which 7,554 remain restricted with scheduled lapses through June 4, 2029.
STERIS plc President and CEO Daniel A. Carestio reported equity compensation and related tax withholding transactions. He received 23,736 ordinary shares as a grant and 82,740 employee stock options with an exercise price of $230.74 per share, expiring in 2036.
On the same date, 2,369 restricted shares vested, and 995 of those shares were withheld at $209.76 per share to cover employment and tax obligations, rather than sold in the market. After these transactions, he directly owned 73,578 ordinary shares, of which 50,113 were restricted as of June 2, 2026, subject to a multi-year vesting schedule.
STERIS plc senior vice president and CFO Karen L. Burton reported routine equity compensation changes. She received a grant of 5,325 ordinary shares at a stated price of $0.0000 per share and now directly holds 13,530 ordinary shares. Footnotes state that as of June 2, 2026, 10,239 of these ordinary shares are restricted, with restrictions scheduled to lapse in several tranches between June 3, 2026 and June 4, 2029. The filing also records withholding of 66 shares from 225 restricted shares that vested on June 2, 2026 to cover taxes, valued at the NYSE closing market price of $209.76 per share. In addition, Burton received an employee stock option for 18,564 ordinary shares at an exercise price of $230.74 per share, expiring on June 2, 2036, which becomes exercisable in four equal installments from June 2, 2027 through June 3, 2030.
STERIS plc director Pierre Boulud received a grant of 367 Career Restricted Stock Units. These derivative awards were acquired at a price of 0.0000 per unit and are linked to 367 underlying STERIS ordinary shares.
Each Career Restricted Stock Unit represents the right to receive one ordinary share six months after the end of his Board service. The units are fully vested immediately but will only be settled in shares six months after his service on the Board ceases. Following this grant, he holds 367 Career Restricted Stock Units directly.
STERIS plc director Richard C. Breeden reported option exercises and share sales. On 2026-06-02, he exercised options to acquire 3,781 Ordinary Shares at $71.40 per share and sold 1,481 Ordinary Shares in an open-market transaction at a weighted average price of $209.51 per share.
Following these transactions, Breeden directly owned 38,964 Ordinary Shares. A separate entry shows 27,242 Ordinary Shares held indirectly, with footnotes explaining these are owned through Breeden-affiliated investment entities and that he may be deemed an indirect beneficial owner, while disclaiming beneficial ownership of 1,358 of those shares.